Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology

Next Previous
Trial Profile

Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms JMIG; PROCLAIM
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 04 May 2018 Results of subgroup analysis assessing impact of PET on overall survival and progression-free survival published in the Journal of Thoracic Oncology.
    • 11 Oct 2016 Results from post-hoc subgroup analyses based on positron emission tomography (PET) scan use in non-small cell lung cancer patients presented at the 41st European Society for Medical Oncology Congress.
    • 07 Jun 2016 Results (n=555) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top